About NextVivo
NextVivo is a company based in Palo Alto (United States) founded in 2021 by Calvin Kuo, Mark Davis, and Adam Margolin. It operates as a HealthTech. NextVivo has raised $7.9 million across 1 funding round from investors including ARE, Khosla Ventures and Wilson Sonsini Goodrich & Rosati. The company has 8 employees as of December 31, 2022. NextVivo offers products and services including Immune Organoid Technology. NextVivo operates in a competitive market with competitors including Newcells Biotech, InSphero, Pandorum, Vivodyne and Adapsyn, among others.
- Headquarter Palo Alto, United States
- Employees 8 as on 31 Dec, 2022
- Founders Calvin Kuo, Mark Davis, Adam Margolin
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$7.9 M (USD)
in 1 rounds
-
Latest Funding Round
$7.9 M (USD), Series A
Dec 09, 2021
-
Investors
ARE
& 2 more
-
Employee Count
8
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NextVivo
NextVivo offers a comprehensive portfolio of products and services, including Immune Organoid Technology.
Organoids are developed for drug testing and therapy.
People of NextVivo
Unlock access to complete
Unlock access to complete
Funding Insights of NextVivo
NextVivo has successfully raised a total of $7.9M through 1 strategic funding round. The most recent funding activity was a Series A round of $7.9 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NextVivo
NextVivo has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Khosla Ventures and Wilson Sonsini Goodrich & Rosati.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage startups are funded by this venture capital firm.
|
Locked | Locked | Locked | |
|
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US
|
Locked | Locked | Locked | |
|
Provider of legal services to technology and life science companies
|
Locked | Locked | Locked |
Investor details for NextVivo
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NextVivo
Investment portfolio details for NextVivo
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NextVivo
Detailed financials for NextVivo
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nextvivo Comparisons
Peer comparison for NextVivo
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NextVivo
NextVivo operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Newcells Biotech, InSphero, Pandorum, Vivodyne and Adapsyn, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Induced pluripotent stem cell-derived organoid models are developed for research.
|
|
| Locked | Locked | Locked |
Cell-based assays and 3D microtissues for drug screening are developed.
|
|
| Locked | Locked | Locked |
Regenerative medicine and 3D tissues are developed for therapeutic uses.
|
|
| Locked | Locked | Locked |
Developer of AI-based platform for lab-grown human tissues
|
|
| Locked | Locked | Locked |
Provider of computational tools for bacterial metabolomic and genomic data analysis
|
|
| Locked | Locked | Locked |
Scalable processes for organoid expansion are developed.
|
Detailed competitors of NextVivo
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nextvivo
Complete news archive for NextVivo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NextVivo
NextVivo was founded in 2021.
NextVivo is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Adam Margolin is the current CEO of NextVivo. They have also founded this company.
NextVivo is a funded company, having raised a total of $7.9M across 1 funding round to date.
As of Dec 31, 2022, the latest employee count at NextVivo is 8.
NextVivo is focused on the development of immune organoid technology for drug discovery and therapy testing. Holistic 3D models of healthy and diseased tissues are created, retaining key immune cell interactions. Solutions are applied to generate and test therapies for cancer, infections, and autoimmune disorders within human-derived models. The biotechnology sector is primarily targeted with innovative approaches to improve drug safety and efficacy.
NextVivo's top competitors include Newcells Biotech, InSphero and Vivodyne.
NextVivo offers Immune Organoid Technology.
NextVivo has 3 investors. Key investors include ARE, Khosla Ventures, and Wilson Sonsini Goodrich & Rosati.